Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Toremifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 9/20 | 0.80 |
| ▸ | ESR2 known ✓ | Q92731 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 3/20 | 0.80 |
| ▸ | TP53 | P04637 | 3/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | GMNN | O75496 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.80 |
| ▸ | TSHR | P16473 | 1/20 | 0.80 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
| ▸ | THPO | P40225 | 1/20 | 0.80 |
| ▸ | HTT | P42858 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toremifene SCHEMBL4564 | 1.00 | ESR1 (0.80) | ESR1LMNAESR2MEN1TP53 | |
| Toremifene SCHEMBL15576158 | 1.00 | ESR1 (0.80) | ESR1LMNAESR2MEN1TP53 | |
| Toremifene SCHEMBL2367538 | 1.00 | ESR1 (0.80) | ESR1LMNAESR2MEN1TP53 | |
| Toremifene SCHEMBL177941 | 1.00 | ESR1 (0.80) | ESR1LMNAESR2MEN1TP53 | |
| Toremifene SCHEMBL21464516 | 0.96 | ESR1 (0.87) | ESR1LMNAESR2MEN1TP53 | |
| Toremifene SCHEMBL15865397 | 0.89 | ESR1 (0.67) | ESR1LMNAESR2MEN1TP53 | |
| Tamoxifen SCHEMBL4019370 | 0.89 | ESR1 (1.00) | ESR1LMNAESR2MEN1TP53 | |
| Tamoxifen SCHEMBL5328781 | 0.89 | ESR1 (1.00) | ESR1LMNAESR2MEN1TP53 | |
| Tamoxifen SCHEMBL10336277 | 0.89 | ESR1 (1.00) | ESR1LMNAESR2MEN1TP53 | |
| Tamoxifen SCHEMBL17164701 | 0.89 | ESR1 (1.00) | ESR1LMNAESR2MEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3302572-B3 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2024-07-24 | — | — | EP | claimed |
| EP-3689868-B1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2023-09-27 | — | — | EP | claimed |
| EP-3524618-B1 | GLA DOMAINS AS TARGETING AGENTS | GLADIATOR BIOSCIENCES INC (US) | 2023-03-08 | — | — | EP | claimed |
| EP-3441089-B1 | TREATMENT METHODS USING ADENOVIRUS | VASCULAR BIOGENICS LTD (IL) | 2022-12-14 | — | — | EP | claimed |
| US-20250032676-A1 | 3D HYDROGEL COMPOSITE HAVING CANCER CELL APOPTOTIC EFFECT AND PREPARATION METHOD THEREOF | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2025-01-30 | — | — | US | disclosed |